REC-4881
Familial adenomatous polyposis
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, a rare tumor predisposition syndrome. There are currently no FDA-approved therapies for the treatment of FAP. MEK1/2 inhibition to target FAP was identified using phenotypic insights by the Recursion OS.
Learn more on clinicaltrials.gov.
*Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Case study
The challenge:
1
2
The unique how:
The outcome:
Learn more about clinical trial at Recursion.
Clinical trials
